Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF).
CD34+ cells were enriched, using a panning method, from peripheral blood (PB) and bone marrow (BM) of healthy volunteers and of patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF). In healthy volunteers, PB CD34+ cells expressed CD33 and CD13 at a higher frequency than BM CD34+ cells, and PB CD34+ cells contained a greater number of burst-forming units-erythroid (BFU-E) than colony-forming units granulocyte-macrophage (CFU-GM). Administration of G-CSF to healthy volunteers induced a marked increase in the number of PB CD34+ cells, although the proportions of those expressing CD33, CD13, and c-kit among these cells as well as colony-forming ability were not changed before and after G-CSF administration. There were no significant differences in surface antigens on PB CD34+ cells between healthy volunteers and patients after chemotherapy plus G-CSF, except for low expression of c-kit in the PB of patients. However, PB CD34+ cells from patients contained almost the same number of CFU-GM as BFU-E. These results indicate that there were clear differences in the features of CD34+ cells from BM and from PB, and between healthy volunteers and patients after chemotherapy plus G-CSF. Enriched CD34+ cells are useful for analyzing the characteristics of hematopoietic progenitor cells, and such analysis may predict the usefulness of autologous or allogeneic peripheral blood stem cell transplantation.
Suzuki
T
T
Department of Medicine, Jichi Medical School, Tochigi-ken, Japan.
Muroi
K
K
Tomizuka
H
H
Amemiya
Y
Y
Miura
Y
Y
D000328:Adult; D015703:Antigens, CD / Q000032:analysis* / Q000097:blood; D018952:Antigens, CD34; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000097:blood; D001854:Bone Marrow Cells; D018826:CD13 Antigens / Q000032:analysis / Q000097:blood; D002469:Cell Separation; D003114:Colony-Forming Units Assay; D003561:Cytarabine / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy*; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy*; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis / Q000378:metabolism; D016184:Receptors, Colony-Stimulating Factor / Q000032:analysis / Q000378:metabolism; D063268:Sialic Acid Binding Ig-like Lectin 3
D015703:Antigens, CD; D018952:Antigens, CD34; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D011518:Proto-Oncogene Proteins; D016184:Receptors, Colony-Stimulating Factor; D063268:Sialic Acid Binding Ig-like Lectin 3; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases; D018826:CD13 Antigens